Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Insider Acquires $11,824.07 in Stock

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACKGet Rating) insider Gary L. Crocker bought 2,323 shares of the company’s stock in a transaction on Tuesday, May 24th. The shares were bought at an average cost of $5.09 per share, for a total transaction of $11,824.07. Following the transaction, the insider now directly owns 125,872 shares in the company, valued at approximately $640,688.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ MACK opened at $5.49 on Friday. The stock has a market capitalization of $73.62 million, a PE ratio of -39.21 and a beta of 1.68. The stock’s fifty day simple moving average is $5.82 and its two-hundred day simple moving average is $5.26. Merrimack Pharmaceuticals, Inc. has a 12-month low of $3.66 and a 12-month high of $7.41.

Merrimack Pharmaceuticals (NASDAQ:MACKGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter.

Separately, StockNews.com began coverage on Merrimack Pharmaceuticals in a research report on Saturday, May 21st. They set a “sell” rating on the stock.

Several institutional investors have recently bought and sold shares of MACK. Sepio Capital LP boosted its position in shares of Merrimack Pharmaceuticals by 276.2% in the 1st quarter. Sepio Capital LP now owns 296,546 shares of the biopharmaceutical company’s stock worth $1,876,000 after purchasing an additional 217,717 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Merrimack Pharmaceuticals by 63.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 341,685 shares of the biopharmaceutical company’s stock worth $1,650,000 after purchasing an additional 132,122 shares in the last quarter. Bronte Capital Management Pty Ltd. boosted its position in shares of Merrimack Pharmaceuticals by 7.6% in the 1st quarter. Bronte Capital Management Pty Ltd. now owns 578,313 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 40,729 shares in the last quarter. BlackRock Inc. boosted its position in shares of Merrimack Pharmaceuticals by 12.8% in the 3rd quarter. BlackRock Inc. now owns 211,051 shares of the biopharmaceutical company’s stock worth $1,020,000 after purchasing an additional 23,961 shares in the last quarter. Finally, Yakira Capital Management Inc. boosted its position in shares of Merrimack Pharmaceuticals by 20.7% in the 1st quarter. Yakira Capital Management Inc. now owns 88,683 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 15,233 shares in the last quarter. 55.93% of the stock is owned by hedge funds and other institutional investors.

About Merrimack Pharmaceuticals (Get Rating)

Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Recommended Stories

Insider Buying and Selling by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.